Vertex recently said the product may deliver more than $100 million in revenue in the 2025 full year. But it's important to ...

Wondering if CRISPR Therapeutics is still a high risk biotech story or a quietly mispriced opportunity? This breakdown will help you decide whether the current share price makes sense for a long term ...

The company does possess a lot of potential, with its approved gene-editing treatment Casgevy. Unfortunately, sales from that ...

Fintel reports that on December 23, 2025, Needham reiterated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a Buy recommendation. Analyst Price Forecast Suggests 41.91% Upside As of December 21, ...

Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy ...

Anyone who has grown up eating freshwater fish knows the drill. You eat slowly. You chew twice. You stop mid-bite because ...

CRISPR Therapeutics recently drew attention as updates highlighted progress in its gene-editing pipeline, including early-stage studies of CTX310, an in vivo therapy designed to lower LDL cholesterol ...

Scientists have used CRISPR technology to bring back a long-lost gene that could be used to prevent gout and certain types of liver disease.

CRISPR biosensors enable real-time health monitoring with attomolar sensitivity, wearable integration, and multiplex ...

Imagine if you could fix a spelling mistake in a long document with just one click. Now, imagine doing the same with the genetic code of a plant or even a human cell. That’s ...